The Patent Finder

Birkmayer Pharmaceuticals

Also on record
Records under this name other than patents Birkmayer Pharmaceuticals holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 10 of 10 · Back to Birkmayer Pharmaceuticals

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 6,248,552Enzyme-based assay for determining effects of exogenous and endogenous factors on cellular energy production
Formerly held
Term ended
Term ended Oct 24, 2017 · USPTO record
Term endedTerm ended Oct 24, 2017USPTO record
US 6,383,771Enzyme-based assay for determining effects of exogenous and endogenous factors on cellular energy
Formerly held
Lapsed on the fee record
Ended May 7, 2014 · USPTO record
Lapsed on the fee recordEnded May 7, 2014USPTO record
US 4,970,200Agent for treatment of Parkinson's disease
Term ended
Term ended no later than Nov 13, 2010 · Low confidence
Term endedTerm ended no later than Nov 13, 2010Low confidence
US 5,332,727Stable, ingestable and absorbable NADH and NADPH therapeutic compositions
Formerly held
Term ended
Term ended no later than Jul 26, 2014 · Low confidence
Term endedTerm ended no later than Jul 26, 2014Low confidence
US 5,444,053Method for treating symptoms of Alzheimer's with NADH and NADPH
Formerly held
Term ended
Term ended no later than Aug 22, 2015 · Low confidence
Term endedTerm ended no later than Aug 22, 2015Low confidence
US 5,654,288Stable NADH and NADPH compositions for sublingual administration
Formerly held
Term ended
Term ended no later than Aug 5, 2017 · Low confidence
Term endedTerm ended no later than Aug 5, 2017Low confidence
US 5,668,114NADH and NADPH pharmaceuticals for treating hypertension
Formerly held
Term ended
Term ended no later than Sep 16, 2017 · Low confidence
Term endedTerm ended no later than Sep 16, 2017Low confidence
US 5,712,259NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
Formerly held
Term ended
Term ended no later than Jan 27, 2018 · Low confidence
Term endedTerm ended no later than Jan 27, 2018Low confidence
US 5,750,512NADH and NADPH therapeutic agents for nasal, sublingual, rectal and dermal administration
Formerly held
Term ended
Term ended no later than May 12, 2018 · Low confidence
Term endedTerm ended no later than May 12, 2018Low confidence
US 5,952,312NADH and NADPH therapeutic agents for nasal, sublingual, rectal and dermal administration
Formerly held
Term ended
Term ended no later than Sep 14, 2019 · Low confidence
Term endedTerm ended no later than Sep 14, 2019Low confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited